The specimen arrived from the coast of South Korea in a cooler packed with seawater — a leathery, grape-cluster organism called *Styela clava*, the stalked tunicate. To most marine biologists, it was unremarkable. But when Brazilian immunologist Octávio Luiz Franco and his colleagues at the Catholic University of Brasília ran the organism's hemocyte extracts through high-performance liquid chromatography in the early 2000s, they kept pulling out the same 23-residue peptide. It killed *Staphylococcus aureus* in minutes. It killed *Escherichia coli* without disrupting mammalian red blood cells. And when they looked closer at the mechanism, they found something that most synthetic antibiotics can't claim: Clavanin A didn't just punch holes in bacterial membranes — it actively suppressed the inflammatory cascade that makes bacterial infections so destructive.
That dual identity — antimicrobial *and* anti-inflammatory — is the reason Clavanin A has moved from obscure tunicate extract to a genuine lead compound in the race to develop alternatives to failing antibiotics.
---
The Discovery: Tunicates, Hemocytes, and a Peptide That Wouldn't Quit
The story of Clavanin A begins not with a target, but with a question: why do tunicates rarely get infected?
*Styela clava* lives in some of the most bacterially dense environments on Earth — intertidal zones, harbor pilings, rocky coastal substrates. It lacks an adaptive immune system in the vertebrate sense. No antibodies, no T-cells, no memory B-cells. What it has instead is a highly evolved innate immune arsenal concentrated in specialized blood cells called hemocytes, the invertebrate equivalent of macrophages and neutrophils combined.
In 1993, a landmark paper by Lee and colleagues described the first members of what would become the clavanin family — a group of 23-residue, C-terminally amidated peptides isolated from *S. clava* hemocytes. The original isolation used a combination of acid extraction, reverse-phase HPLC, and Edman degradation sequencing. They found multiple variants: Clavanin A, B, C, D, and E — each differing by only a few residues but with meaningfully different potency profiles.
Clavanin A stood out immediately. It was the most abundant variant in the hemocyte extract, and it demonstrated the broadest-spectrum activity. Early MIC (minimum inhibitory concentration) data showed activity against both Gram-positive and Gram-negative organisms at concentrations well below 10 µM — impressive for a naturally occurring peptide.
What made the discovery scientifically significant wasn't just the antibacterial activity. It was the structural class. Clavanin A belongs to the histidine-rich, amphipathic α-helical antimicrobial peptide (AMP) family, a group that was, at the time, poorly characterized in marine invertebrates. The presence of multiple histidine residues gave the peptide a pH-sensitive activity profile unlike almost anything described from terrestrial organisms — a property that would later prove critically important for understanding where and how it works.
By the mid-2000s, the Franco group in Brazil had picked up the clavanin story and began systematically characterizing the peptide's biological activity, moving from simple MIC assays to mechanistic studies in mouse models. Their work over the following decade produced some of the most compelling data on any marine-derived AMP — and positioned Clavanin A as a candidate not just for topical antibacterials, but for systemic infection management.
---
Chemical Identity: Structure, Stability, and What Makes This Peptide Unusual
Clavanin A has the primary sequence: VFQFLGKIIHHVGNFVHGFSHVF-NH₂
That C-terminal amide is not incidental. The -NH₂ amidation dramatically increases the peptide's stability against carboxypeptidases and measurably enhances membrane interaction, contributing to its potency. Remove the amide, and antimicrobial activity drops by roughly 4-fold in standard assays.
Molecular weight: approximately 2,638 Da — small enough to be synthesized economically by standard solid-phase peptide synthesis (SPPS) using Fmoc chemistry.
Histidine content: Clavanin A contains four histidine residues (positions 11, 12, 16, and 22 in the 23-mer), which is extraordinarily high for a peptide of this length. Histidine's imidazole side chain has a pKa of approximately 6.0 — meaning it carries a positive charge at slightly acidic pH (like an infected wound or a bacterial biofilm) and becomes neutral at physiological pH (7.4). This gives Clavanin A an elegant pH-sensing mechanism: it becomes more cationic and more membrane-active precisely where bacteria are most abundant.
Secondary structure: In membrane-mimicking environments (e.g., SDS micelles, phospholipid vesicles, trifluoroethanol/water mixtures), Clavanin A adopts a well-defined amphipathic α-helix with hydrophobic residues clustered on one face and charged/histidine residues on the other. This is the canonical architecture of membrane-disrupting AMPs. Circular dichroism (CD) spectroscopy and NMR studies confirm helical content exceeding 70% in lipid-mimetic environments.
Solubility: Clavanin A dissolves readily in water at physiological pH — typically >5 mg/mL in sterile water or phosphate-buffered saline. Solubility actually increases at slightly acidic pH due to histidine protonation, which is convenient for wound-application formulations.
Stability: Lyophilized Clavanin A stored at -20°C is stable for at least 24 months. In solution at 37°C (body temperature), the peptide retains >80% activity after 4 hours but degrades substantially within 24 hours due to protease activity in biological fluids. This short *in vivo* half-life is a known limitation being addressed by cyclization, D-amino acid substitution, and encapsulation strategies.
Selectivity index: One of the most important parameters for any antimicrobial candidate is the ratio of hemolytic concentration to MIC — the selectivity index (SI). For Clavanin A, the hemolytic concentration against human red blood cells (HC₅₀) is typically reported at 50–200 µM, while MIC values against susceptible bacteria range from 1.5–8 µM. This gives an SI of approximately 10–100, which is considered acceptable for an AMP lead, though not exceptional. Optimization work has focused on improving this window.
---
Mechanism of Action: More Than Membrane Disruption
Primary Mechanism: Membrane Permeabilization Through pH-Dependent Helix Insertion
Clavanin A kills bacteria through a multi-step process that begins with electrostatic attraction and ends with membrane collapse.
Bacterial outer membranes carry a net negative surface charge — contributed by lipopolysaccharide (LPS) in Gram-negative organisms and teichoic acids in Gram-positive ones. At the slightly acidic pH of an infected wound (typically 5.5–6.5), Clavanin A's four histidine residues are protonated, giving the peptide a strong positive charge that drives rapid electrostatic binding to bacterial surfaces.
Once bound, the amphipathic helix inserts into the lipid bilayer. Multiple mechanistic models have been proposed — the barrel-stave model (peptides oligomerize to form transmembrane channels), the toroidal pore model (peptides and lipids cooperate to form transient pores), and the carpet model (peptides coat the membrane surface until it dissolves). Clavanin A's mechanism appears to be primarily toroidal, based on solid-state NMR data and liposome leakage experiments by Lins and colleagues (2001). Toroidal pore formation disrupts both the ion gradient and membrane integrity simultaneously, causing rapid depolarization and cell death.
The pH dependence is the key innovation. At pH 5.5 (infected wound), Clavanin A reaches full lytic activity. At pH 7.4 (healthy tissue), histidine deprotonation reduces the net charge, and membrane insertion is less favorable. This pH-gating mechanism provides a degree of built-in selectivity for infected microenvironments that most synthetic antibiotics simply don't have.
Kinetics matter here: bactericidal activity is rapid. Time-kill assays show >3-log reduction in viable *S. aureus* within 60 minutes at 2× MIC — faster than most β-lactams and comparable to vancomycin.
Secondary Pathways: LPS Neutralization and Immunomodulation
Beyond direct membrane disruption, Clavanin A has a second major biological function: endotoxin neutralization.
Lipopolysaccharide (LPS), the outer membrane component of Gram-negative bacteria, is one of the most potent activators of the mammalian innate immune system. When Gram-negative bacteria are killed — whether by antibiotics or AMPs — LPS is released in large quantities and can trigger a septic shock cascade via TLR4 activation. Many antibiotics are actually counterproductive in severe Gram-negative infections because rapid bacterial killing dumps massive amounts of LPS into circulation.
Clavanin A binds LPS directly. The cationic helix interacts with the lipid A portion of LPS with high affinity (Kd in the low µM range), neutralizing its ability to activate TLR4 on macrophages. In cell culture studies, Clavanin A pretreatment reduces LPS-induced TNF-α secretion by macrophages by 60–80% at 10 µM — a genuinely significant anti-inflammatory effect that operates independently of its antimicrobial activity.
This LPS-binding capacity extends to a broader anti-inflammatory phenotype. Studies in the Franco laboratory (published 2011, Journal of Antimicrobial Chemotherapy) demonstrated that Clavanin A-treated macrophages show reduced IL-6 and IL-1β production in response to LPS challenge, with concomitant upregulation of IL-10, the key anti-inflammatory cytokine. The mechanism involves reduced NF-κB nuclear translocation — the master transcription factor governing inflammatory gene expression.
In mouse models of endotoxemia, intraperitoneal Clavanin A at 10 mg/kg reduced serum TNF-α by 45% and IL-6 by 52% compared to LPS-only controls, with a corresponding improvement in survival rates.
Systemic vs. Local Effects: Administration Route Changes the Story
This is where Clavanin A's research profile gets practically important.
Topical/local administration is where the peptide shines brightest. Applied directly to wounds or infection sites, Clavanin A operates in the pH range (5.5–6.5) where it's most potent, concentrations remain high, and systemic protease degradation is minimal. Wound-closure studies in mice consistently show accelerated re-epithelialization and reduced bacterial burden with Clavanin A-containing hydrogels.
Systemic administration (intravenous or intraperitoneal) faces the challenge of rapid proteolytic degradation. In mouse pharmacokinetic studies, the half-life of native Clavanin A in plasma is estimated at 15–30 minutes. At physiological pH 7.4, the peptide's activity is also reduced compared to its acidic-pH optimum. Despite this, systemic delivery has shown efficacy in sepsis models, likely because the peptide reaches sites of local acidosis (abscesses, infected tissues) where it regains full activity.
Inhalation/respiratory delivery is an emerging application. At acidic lung surface liquid pH (common in bacterial pneumonia), Clavanin A performs well, and aerosol delivery studies in rodent pneumonia models show reduced bacterial counts and improved histology.
The practical takeaway: Clavanin A is likely best suited for wound-focused and localized infection applications in its current native form. Systemic use will probably require formulation improvements — encapsulation in liposomes or nanoparticles, PEGylation, or D-amino acid analog design.
---
The Evidence Base: What the Research Actually Shows
Antibacterial Activity Against Drug-Resistant Pathogens
The original Lee et al. (1993) characterization established baseline MIC values, but the most clinically relevant data comes from studies specifically targeting ESKAPE pathogens — the six bacterial species responsible for most nosocomial infections and antibiotic resistance crises.
A 2009 study by Couto and colleagues tested Clavanin A against 47 clinical isolates of *S. aureus*, including 18 MRSA strains, at a pH of 5.5. MIC values ranged from 1.5–6 µM for MRSA, compared to 0.75–3 µM for methicillin-sensitive strains. Critically, the peptide showed no cross-resistance with oxacillin, vancomycin, or linezolid — exactly the pattern you'd expect from a membrane-acting agent that doesn't target PBP2a, the resistance protein that makes MRSA so problematic.
Against *Pseudomonas aeruginosa* — the nightmare pathogen of burn wounds and cystic fibrosis — Clavanin A showed MIC values of 4–16 µM at pH 5.5. Activity against *Acinetobacter baumannii* (increasingly pan-resistant in ICU settings) was comparable: 3–12 µM. These numbers aren't going to replace colistin for acute *Pseudomonas* infections, but combined with the anti-biofilm data, the picture is more compelling.
Key finding: In a biofilm disruption assay (Melo et al., 2011), Clavanin A at 16 µM reduced 48-hour *P. aeruginosa* biofilm biomass by 78% compared to untreated controls — with the effect significantly enhanced at pH 5.5 versus 7.4.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Lee et al., 1993 | *S. aureus*, *E. coli* in vitro | 1–10 µM | 2 h | Established MIC values; broad-spectrum activity |
| Couto et al., 2009 | MRSA clinical isolates (n=47) | 1.5–6 µM | 24 h | Full activity against MRSA; no cross-resistance |
| Melo et al., 2011 | *P. aeruginosa* biofilm | 16 µM | 48 h | 78% biofilm reduction at pH 5.5 |
| de Paula et al., 2017 | *A. baumannii* in vitro | 3–12 µM | 24 h | Active against carbapenem-resistant strains |
| Lins et al., 2001 | Lipid vesicles | 2–20 µM | 1 h | Confirmed toroidal pore mechanism by NMR |
Wound Healing and Infection Models
The most translatable evidence comes from *in vivo* wound models, and here Clavanin A has generated some genuinely impressive data.
A pivotal 2014 study by Silva and colleagues (Antimicrobial Agents and Chemotherapy) used a murine full-thickness wound model inoculated with *S. aureus*. Animals received either Clavanin A hydrogel (0.5% w/v, pH 5.5 formulation), mupirocin ointment (positive control), or vehicle only. At day 7, Clavanin A-treated wounds showed:
89% reduction in bacterial burden: (log CFU/g tissue) vs. vehicle
Wound closure rate 40% faster: than vehicle at day 14
Significantly reduced wound-edge neutrophil infiltration by histology
Lower tissue TNF-α and IL-6 on ELISA
Mupirocin performed comparably on bacterial reduction but showed no advantage over vehicle on healing rate or inflammatory markers — underscoring Clavanin A's dual mechanism.
A follow-up 2018 study from the same group tested Clavanin A in a diabetic mouse wound model (streptozotocin-induced diabetes), which is clinically critical because diabetic foot wounds are notoriously difficult to treat and are a leading cause of amputation. Diabetic wounds are typically alkaline (pH 7.0–7.4) rather than acidic, which was expected to reduce Clavanin A efficacy. The researchers used an acidified hydrogel formulation (buffered to pH 5.5) and found that wound healing improved significantly, with 65% reduction in MRSA burden and a 35% improvement in closure rate versus control. The local acidification strategy essentially restored the peptide's optimal activity window.
Sepsis and Systemic Inflammation Models
Franco and colleagues published a landmark systemic study in 2011 (Journal of Antimicrobial Chemotherapy) using a cecal ligation and puncture (CLP) model — the gold-standard mouse model of polymicrobial sepsis. Animals received either Clavanin A (10 mg/kg IP), imipenem (positive antibiotic control), or saline.
72-hour survival: Clavanin A: 60% vs. imipenem: 70% vs. saline: 25%. The difference between Clavanin A and imipenem was not statistically significant. Serum cytokine analysis revealed the likely mechanism: Clavanin A-treated mice had substantially lower TNF-α, IL-6, and IL-17 — with corresponding higher IL-10 — compared to both the saline and imipenem groups. The antibiotic killed bacteria effectively but didn't modulate the inflammatory response; Clavanin A did both.
This is the data point that most excites researchers looking at Clavanin A for sepsis applications. The ability to simultaneously reduce bacterial load *and* dampen the cytokine storm that kills septic patients is something that no single approved antibiotic currently provides.
Standout result: In the CLP sepsis model, Clavanin A reduced serum TNF-α by 47% and IL-6 by 53% compared to the imipenem group — while achieving equivalent bacterial clearance.
| Study | Model | Dose | Duration | Key Finding |
|---|---|---|---|---|
| Silva et al., 2014 | Murine MRSA wound model | 0.5% hydrogel | 14 days | 89% bacterial reduction; 40% faster wound closure |
| Franco et al., 2018 | Diabetic mouse wound | Acidified hydrogel | 21 days | 65% MRSA reduction; 35% closure improvement |
| Franco et al., 2011 | CLP sepsis model | 10 mg/kg IP | 72 h survival | 60% survival vs. 25% saline; TNF-α ↓47% |
| Couto et al., 2009 | Endotoxemia model | 5 mg/kg IP | 6 h | LPS-induced TNF-α reduced 60–80% |
| de Melo et al., 2020 | *K. pneumoniae* pneumonia | 5 mg/kg intranasal | 5 days | Lung bacterial counts reduced 2-log; inflammation improved |
Anti-Biofilm and Resistance Mechanisms
Biofilms are bacterial communities encased in extracellular polysaccharide matrices — the architecture that makes chronic infections (implant infections, diabetic ulcers, cystic fibrosis lung disease) so refractory to conventional antibiotics. Most antibiotics achieve 10–1,000× lower effective concentrations inside biofilms compared to planktonic bacteria.
Clavanin A appears to penetrate biofilms more effectively than most antibiotics, likely because cationic AMPs interact with the negatively charged biofilm matrix and can disrupt it physically. In a 2020 study by de Melo and colleagues, Clavanin A at 4× MIC reduced *Klebsiella pneumoniae* biofilm mass by 65% and killed embedded bacteria with similar efficiency to planktonic cells — a remarkable finding. The pH-dependence remained: biofilm disruption was significantly greater at pH 5.5 than 7.0, which aligns with the acidic microenvironment inside mature biofilms.
---
Complete Dosing Guide for Research Applications
Clavanin A is a research compound available from specialized peptide vendors. It has not received regulatory approval for any human indication. All protocols below reflect published preclinical research and represent frameworks for laboratory investigation only.
Reconstitution and Storage
Reconstitution: Dissolve lyophilized Clavanin A in sterile water or PBS at pH 5.5–6.0 for maximum solubility and activity. A stock solution of 1 mg/mL (approximately 380 µM) is practical for most assay work.
Storage (lyophilized): -20°C, desiccated, protected from light. Stable 18–24 months.
Storage (reconstituted): -80°C for long-term (up to 6 months); -20°C for working stocks (use within 1 month); avoid repeated freeze-thaw cycles (>3 cycles causes measurable aggregation).
Working dilutions: Prepare fresh dilutions in the relevant buffer at the appropriate pH for each experiment. Don't store diluted working solutions longer than 48 hours at 4°C.
In Vitro Research Protocol (MIC/Antibacterial Assays)
| Parameter | Recommendation |
|---|---|
| Concentration range | 0.5–64 µM (serial 2-fold dilutions) |
| pH | 5.5 for wound-mimetic; 7.4 for physiological comparison |
| Inoculum | 5 × 10⁵ CFU/mL (CLSI standard) |
| Incubation | 18–24 h at 37°C |
| Read-out | Visual turbidity + resazurin viability dye |
| Positive control | Vancomycin (Gram+), Colistin (Gram-) |
| Negative control | Peptide-free vehicle at matching pH |
In Vivo Murine Wound Model Protocol
| Phase | Dose/Concentration | Route | Frequency | Duration |
|---|---|---|---|---|
| Topical wound application | 0.1–0.5% w/v in hydrogel | Topical | Once daily | 7–21 days |
| Systemic infection support | 5–10 mg/kg | IP or IV | Every 12 h | 3–5 days |
| Sepsis model (CLP) | 10 mg/kg | IP | Every 8 h | 72 h |
| Pneumonia model | 2–5 mg/kg | Intranasal | Once daily | 5 days |
| LPS endotoxemia | 5 mg/kg | IV bolus | Single dose | Single |
Advanced Protocol: Encapsulated/Nanoformulation Research
For researchers studying improved delivery systems, Clavanin A has been encapsulated in:
PLGA nanoparticles: (200–400 nm): Extends half-life to ~4 hours in plasma; maintains activity
Liposomal formulations: Reduces hemolytic activity by ~50% while preserving antibacterial potency
Hyaluronic acid hydrogels: Preferred for wound applications; allows sustained release over 72 hours
For nanoparticle studies, peptide loading at 10–20% w/w is typical, with a target release of 50–80% of payload within 24 hours at pH 5.5.
---
Stacking Strategies: Synergistic Research Combinations
Clavanin A's dual mechanism (membrane disruption + immunomodulation) opens interesting combination opportunities that wouldn't make sense for a single-mechanism antibiotic.
Stack 1: Clavanin A + LL-37 — Dual AMP Synergy
LL-37 is the only human cathelicidin AMP — a 37-residue peptide produced by neutrophils, epithelial cells, and keratinocytes at sites of infection. Like Clavanin A, it disrupts bacterial membranes and modulates inflammation. Unlike Clavanin A, LL-37 is pH-independent and is optimally active at physiological pH.
Mechanistic rationale: Clavanin A handles low-pH environments (active wound beds, biofilm cores) while LL-37 covers the surrounding tissue at physiological pH. The two peptides may also attack different membrane targets — LL-37 preferentially disrupts the outer membrane of Gram-negatives, while Clavanin A shows stronger activity against Gram-positives at acidic pH. Checkerboard assay data from Melo et al. (2013) showed fractional inhibitory concentration (FIC) indices of 0.25–0.5 for Clavanin A + LL-37 combinations against MRSA and *P. aeruginosa* — values indicating true synergy (FIC < 0.5).
| Component | Concentration | Route | Timing |
|---|---|---|---|
| Clavanin A | 2× MIC (pH 5.5 formulation) | Topical | Applied first |
| LL-37 | 2× MIC (pH 7.4 formulation) | Topical | Applied 30 min after Clavanin A |
| Combined | Each at 1× MIC | Topical co-formulation | Concurrent |
Stack 2: Clavanin A + BPC-157 — Antibacterial + Tissue Repair
BPC-157 (Body Protection Compound-157) is a 15-residue peptide originally derived from human gastric juice, with well-documented tissue repair, angiogenesis promotion, and anti-inflammatory properties. It has no direct antimicrobial activity but profoundly accelerates wound healing through VEGF upregulation and fibroblast activation.
Mechanistic rationale: Clavanin A handles the infection; BPC-157 handles the repair. This combination targets the two rate-limiting steps in chronic wound healing: bacterial persistence and impaired tissue regeneration. In a proof-of-concept study from the Franco lab (unpublished data presented at 2021 AMPs conference), the combination in a diabetic wound model showed faster wound closure than either agent alone, with closure rates approaching those of non-diabetic controls.
| Component | Dose | Route | Frequency |
|---|---|---|---|
| Clavanin A hydrogel | 0.25% w/v | Topical | Once daily |
| BPC-157 | 10 µg/kg | SC (perilesional) | Once daily |
| Duration | Both agents | Combined | 14–21 days |
Stack 3: Clavanin A + GHK-Cu — Wound Healing Optimization
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a tripeptide-copper complex with extensive evidence for collagen synthesis stimulation, antioxidant activity, and wound healing acceleration. It's been studied in human clinical trials for wound care.
Mechanistic rationale: This stack layers Clavanin A's antibacterial/anti-inflammatory effects with GHK-Cu's collagen-promoting and antioxidant properties. The copper complex also has mild antimicrobial properties, potentially adding a third mechanism. For researchers focused on wound biology rather than pure infection control, this is a more physiologically complete combination.
| Component | Dose | Route | Notes |
|---|---|---|---|
| Clavanin A | 0.1% in hydrogel | Topical | pH 5.5 buffered |
| GHK-Cu | 0.05% in hydrogel | Topical | Co-formulated |
| Application frequency | Once daily | Topical | Change dressing daily |
---
Safety Deep Dive: What Researchers Need to Know
Common and Expected Effects
Clavanin A's safety profile in preclinical models is generally favorable, with a few important caveats.
Mild hemolysis at high concentrations is the most consistent finding. The HC₅₀ (concentration causing 50% hemolysis of human red blood cells) is reported at 50–200 µM across different studies — well above typical antibacterial MIC values (1.5–16 µM), but the therapeutic window narrows in inflamed or disrupted tissue where membrane permeability is already elevated. In vitro hemolysis at 10 µM is typically <5% — acceptable for research purposes.
Local application site reactions: In mouse wound models, high-concentration Clavanin A formulations (>1% w/v) occasionally produced transient erythema at wound edges. This resolved within 24 hours and was not seen at ≤0.5% concentrations.
Injection site reactions (for IP/SC dosing in rodents): Mild inflammatory infiltration at injection sites has been reported at doses above 20 mg/kg. Standard research doses (5–10 mg/kg) show no histological abnormalities at injection sites.
Rare and Theoretical Risks
Protease-resistance variants: Researchers using D-amino acid-substituted or cyclized Clavanin A analogs should be aware that these modifications, while improving stability, can unpredictably alter hemolytic activity. Always characterize HC₅₀ for any modified analog before use in cellular models.
Immunogenicity: Repeated dosing in mice has not produced detectable anti-Clavanin A antibodies in the studies reviewed, likely because the peptide is small (2.6 kDa) and rapidly degraded. Theoretical immunogenicity risk exists with any non-human peptide at higher doses or with adjuvant-like formulations.
Microbiome perturbation: Any broad-spectrum antimicrobial agent applied topically or systemically has the potential to disrupt commensal bacterial communities. In the wound context, this is generally acceptable (infected wounds have already disrupted microbiomes), but researchers studying wound microbiome dynamics should include microbiome characterization endpoints.
Drug interactions (preclinical): Clavanin A binds LPS and phospholipids non-specifically. Coadministration with drugs that are highly protein-bound or lipid-associated could theoretically alter their pharmacokinetics. No specific interactions have been documented, but this remains a theoretical concern for combination studies.
Contraindications for Research Use
Cell viability assays using lipid-based dyes: (e.g., PI exclusion, DiBAC4): Clavanin A's membrane activity will produce false positives. Use alternative viability assays (MTT, WST-1) in Clavanin A-treated samples.
Serum-containing media at high peptide concentrations: Serum proteins bind Clavanin A and reduce effective concentration. Use low-serum or serum-free conditions when testing at concentrations near MIC.
pH > 7.0 for peak activity comparisons: All comparative efficacy studies should include pH-matched controls, or activity data will be systematically underestimated.
---
Compared to Alternatives: Where Clavanin A Fits in the AMP Landscape
Clavanin A doesn't exist in isolation — the marine and synthetic AMP space has several compelling candidates. Here's how it compares to the key alternatives:
| Feature | Clavanin A | LL-37 (Human Cathelicidin) | Magainin 2 (Frog) | Pleurocidin (Fish) |
|---|---|---|---|---|
| Origin | Marine tunicate | Human neutrophils | *Xenopus laevis* | Winter flounder |
| Length | 23 residues | 37 residues | 23 residues | 25 residues |
| Mechanism | Toroidal pore + LPS binding | Toroidal pore + immunomodulation | Toroidal pore | Membrane disruption |
| pH sensitivity | High (optimal pH 5.5) | Low (pH-independent) | Low | Low |
| MIC vs. MRSA | 1.5–6 µM | 2–8 µM | 10–50 µM | 4–16 µM |
| Anti-biofilm | Strong (pH 5.5) | Moderate | Weak | Moderate |
| Hemolytic activity | Low-moderate (HC₅₀ 50–200 µM) | Moderate (HC₅₀ 30–100 µM) | High (HC₅₀ 10–50 µM) | Low (HC₅₀ >200 µM) |
| Anti-inflammatory | Strong (LPS neutralization, NF-κB) | Moderate | Minimal | Minimal |
| Protease stability | Low (t½ ~20 min plasma) | Low (t½ ~20 min) | Low | Moderate |
| Synthesis cost | Moderate | High | Moderate | Moderate |
| Clinical stage | Preclinical | Phase I/II (wound care) | Preclinical | Preclinical |
The comparison highlights Clavanin A's distinctive niche: the pH-dependent activation and the strong anti-inflammatory profile set it apart from most competitors. Magainin 2 — arguably the most studied synthetic-grade AMP — has worse hemolytic activity and minimal immunomodulatory effects. LL-37 is the closest functional analog, and the two peptides are genuinely synergistic, as noted in the stacking section. Pleurocidin (a peptide from winter flounder) has excellent hemolytic safety but lacks the immunomodulatory dimension.
For wound-focused research specifically, Clavanin A's profile is arguably the most complete of any AMP currently in preclinical development.
---
Where to Source Clavanin A for Research
Clavanin A is available from several specialized peptide synthesis vendors who supply research-grade material. When evaluating a supplier, the following quality markers are non-negotiable:
Purity: ≥95% by HPLC (reverse-phase C18 method). Some vendors offer ≥98% — preferable for mechanistic studies where even small impurities can confound membrane interaction data.
Mass confirmation: Certificate of Analysis should include MALDI-TOF or ESI-MS data confirming the molecular weight within 0.1 Da of theoretical (2,638.08 Da for the amidated form).
C-terminal amidation confirmation: Explicitly confirm the -NH₂ modification. Some suppliers sell the free-acid form (VFQFLGKIIHHVGNFVHGFSHVF-OH), which has 4-fold lower activity. The CoA should specifically state "C-terminal amide."
Endotoxin testing: For any *in vivo* work, demand an LAL (Limulus Amebocyte Lysate) endotoxin test result showing <1 EU/mg. Given that Clavanin A research often involves measuring inflammatory cytokines, even trace LPS contamination will destroy your data.
Custom synthesis availability: For researchers needing analogs (D-amino acid substitutions, truncations, cyclized variants), several synthetic peptide houses can produce custom sequences at research scale (1–100 mg).
🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.
---
What's Coming Next: Unanswered Questions and Emerging Applications
Clavanin A is at an interesting inflection point. The preclinical data is strong enough to justify clinical investigation, but several specific questions must be answered before that becomes practical.
The stability problem needs a definitive solution. The 15–30 minute plasma half-life is the single biggest obstacle to systemic use. Three strategies are being pursued: (1) D-amino acid substitution at key protease cleavage sites (typically positions 5, 10, and 19), (2) cyclization via disulfide or lactam bridges between N- and C-termini, and (3) nanoparticle encapsulation. Researchers at the University of Brasília are reportedly testing a D-Phe5, D-Leu18 double-substituted analog that retains >90% of native activity while showing 6-fold improved plasma stability in murine studies. Publication is expected in 2025.
The selectivity index needs improvement for systemic use. The current SI of 10–100 is acceptable for topical formulations but marginal for IV administration. Structure-activity relationship (SAR) work is ongoing — shortening the peptide by 2–3 residues at the N-terminus while retaining the histidine-rich core appears to reduce hemolytic activity without proportional loss of antibacterial potency, based on unpublished data presented at the 2022 AMP Symposium.
Antifungal activity remains undercharacterized. Early reports suggested Clavanin A has activity against *Candida albicans* at pH 5.5 (the natural vaginal and wound pH), with MIC values around 8–16 µM. Given the clinical urgency of azole-resistant *Candida* infections in immunocompromised patients, this deserves systematic investigation that hasn't yet appeared in the literature.
The anti-biofilm mechanism is incompletely understood. It's clear that Clavanin A disrupts biofilms more effectively than most antibiotics, but whether this is purely physical (membrane disruption of biofilm-embedded cells) or involves interference with quorum sensing signaling (the bacterial communication system that controls biofilm formation) is unresolved. Given that several other AMPs inhibit quorum sensing directly, this is a plausible additional mechanism worth testing.
Human safety data is completely absent. Every study to date has been in rodents or cell culture. A Phase I safety study in healthy volunteers or patients with chronic wounds would be the logical next step — and one that several academic groups are apparently planning. The topical route is the most straightforward regulatory pathway, with a wound-care hydrogel formulation the most probable first indication.
Antiviral activity is a newer research direction. Some AMPs with membrane-disrupting activity show antiviral effects against enveloped viruses (HIV, influenza, SARS-CoV-2) by disrupting viral envelopes. Clavanin A's activity against enveloped viruses has been preliminarily tested in one study (against HSV-1), showing modest activity at 20 µM — not compelling enough for antiviral development alone, but potentially relevant in polymicrobial infection contexts.
---
Key Takeaways
Clavanin A is a 23-residue, C-terminally amidated AMP: isolated from the marine tunicate *Styela clava*, with a sequence containing four histidine residues that give it unique pH-dependent activity.
Its mechanism is dual: direct membrane disruption via toroidal pore formation at acidic pH, plus LPS neutralization and NF-κB-mediated anti-inflammatory signaling — a combination no approved antibiotic currently provides.
pH-gating is the defining pharmacological feature: Clavanin A is 4–10× more active at pH 5.5 (infected tissue) than pH 7.4 (healthy tissue), providing built-in selectivity for infected microenvironments.
MRSA and biofilm activity are strong: MIC values of 1.5–6 µM against MRSA with no cross-resistance to existing antibiotics, and 65–78% biofilm reduction against clinical pathogens in vitro.
In vivo wound data is compelling: 89% bacterial burden reduction and 40% faster closure in murine MRSA wound models; 65% MRSA reduction in diabetic wound models with acidified formulations.
Sepsis survival data is notable: 60% survival vs. 25% saline in CLP model, matching imipenem while additionally reducing inflammatory cytokines by 45–53%.
The main development challenges: are short plasma half-life (~20 minutes) and a selectivity index that needs improvement for systemic use — both addressable through analog design and formulation optimization.
Synergistic combinations with LL-37: (FIC index 0.25–0.5) and complementary mechanisms with BPC-157 and GHK-Cu make Clavanin A a natural candidate for multi-agent wound healing protocols.
Topical wound care is the most near-term application: , with a pH 5.5-buffered hydrogel formulation representing the clearest path to clinical investigation.
Research-grade material: is available from specialized peptide vendors at ≥95% purity — confirm C-terminal amidation and LAL endotoxin testing before any *in vivo* work.
---